Article Sidebar
Views PDF: 89
EVALUATION OF THE LYTIC EFFECTS OF CAR-T CELLS ON CD19+ CANCER CELL LINES
Main Article Content
Abstract
Objectives: To evaluate lytic effects of CAR-T on CD19+ cancer cell lines. Methods: Experimental, descriptive, cross-sectional study with control groups. Daudi, 1D2 (CD19+) and K562 (CD19-) cancer cell lines were labelled with CFSE. CAR-T or PBMC cells (effector) were added to the culture wells containing CD19+ or K562 cancer cells (target) with the target:effector ratio (T:E) of 1:2, 1:5, 1:10. The cells were incubated at 37ºC, 5% CO2 for 6 hours, then analyzed by flow cytometry. Results: CAR-T had the ability to lyse CD19+ cancer cells, and the lysis ability increased according to the ratio of CAR-T co-cultured with CD19+ cells. The difference was statistically significant when compared to control groups (PBMC and CD19-) (p < 0.05). Conclusion: CAR-T cells exhibit the ability to lyse CD19+ cancer cell lines.
Article Details
Keywords
CAR-T, CD19
References
2. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics. CA Cancer J Clin. Sep-Oct 2010;60(5):277-300.
3. Judith F, Steuber C, Poplack D. Acute lymphoblastic leukemia. Princile and Practice of Pediattric Oncology. 2005.
4. Terwilliger T, Abdul-Hay M. Acute lymphoblastic leukemia: A comprehensive review and 2017 update. Blood Cancer Journal. Jun 30 2017;7(6):e577. DOI:10.1038/bcj.2017.53
5. Vormittag P, Gunn R, Ghorashian S, Veraitch FS. A guide to manufacturing CAR T cell therapies. Curr Opin Biotechnol. Oct 2018;53:164-181.
6. Mock U, Nickolay L, Philip B, et al. Automated manufacturing of chimeric antigen receptor T cells for adoptive immunotherapy using CliniMACS prodigy. Cytotherapy. Aug 2016;18(8):1002-1011. DOI:10.1016/ j.jcyt.2016.05.009
7. Poorebrahim M, Sadeghi S, Fakhr E, et al. Production of CAR T-cells by GMP-grade lentiviral vectors: latest advances and future prospects. Critical Reviews in Clinical Laboratory Sciences. Sep 2019;56(6):393-419. DOI:10.1080/ 10408363.2019.1633512
8. Casati A, Varghaei-Nahvi A, Feldman SA, et al. Clinical-scale selection and viral transduction of human naïve and central memory CD8+ T cells for adoptive cell therapy of cancer patients. Cancer Immunol Immunother. Oct 2013;62(10):1563-73. DOI:10.1007/s00262-013-1459-x
9. Kebriaei P, Singh H, Huls MH, et al. Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells. J Clin Invest. Sep 1 2016;126(9):3363-76. DOI:10.1172/jci86721
10. Wang L, Gong W, Wang S, et al. Improvement of in vitro potency assays by a resting step for clinical-grade chimeric antigen receptor engineered T cells. Cytotherapy. May 2019;21(5):566-578. DOI:10.1016/j.jcyt.2019.02.013
11. Maude SL, Frey N, Shaw PA, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. Oct 16 2014;371(16): 1507-17. DOI:10.1056/NEJMoa1407222
12. Grupp SA, Kalos M, Barrett D, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med. Apr 18 2013;368(16):1509-1518.